个性化文献订阅>文章检索

文章名     作者     期刊名     摘要     卷     期         如果没有找到您所需要的文献，请点击 ——此处申请     共7条记录   Pharmaceutical Development of IPI-504, an Hsp90 Inhibitor and Clinical Candidate for the Treatment of Cancer [作者：Porter, JR; Adams, J; Ahn, R; Ammoscato, V; Arsenault, B; Austad, BC; Baker, G; Basuki, J; Booth, MR; Campbell, MJ; Carter, B; Curtis, M; Depew, K; Douglas, MA; Ge, J; Grenier, L; Helble, J; Henderson, J; Goltz, N; Ionescu, D; Kott, L; Kropp, JT; Lee, J; Li, KM; Maurer, B; Mayes, D; Pak, RH; Piotrowski, J; Porter, JR; Rusch, D; Sylvester, GE; Wong, S; Wright, J,期刊：Drug Development Research, 页码：429-438 , 文章类型： Article，,卷期：2010年71-7] IPI-504 (retaspimycin hydrochloride) is an Hsp90 inhibitor that is the subject of multiple clinical trials for the treatment of cancer. IPI-504 is an aqueous soluble (> 200 mg/ml) hydroquinone hydrochloride salt of 17-(a... State-of-the-Art Process for the Safe Synthesis of Anticancer Drugs [作者：Ammoscato, V; Wickenheiser, R; Henderson, J; Munk, S,期刊：Drug Development Research, 页码：439-444 , 文章类型： Article，,卷期：2010年71-7] Most cancer drugs are quite potent and represent a potential hazard to chemists conducting their synthesis. Chemical development teams must therefore integrate proper handing techniques for such compounds into their deve... Managing High-Potency Active Pharmaceutical Ingredients-A Drug Sponsor's Guide [作者：Wollowitz, S,期刊：Drug Development Research, 页码：420-428 , 文章类型： Review，,卷期：2010年71-7] The wide interest in developing improved therapies for cancer has led to a dramatic increase in the number of highly potent active pharmaceutical ingredients (HAPIs) under development and in use today. The following is a... Metabolic Limitations of the Use of Nucleoside Analogs in Cancer Therapy May Be Overcome by Application of Nanoparticles as Drug Carriers: A Review [作者：Hajdo, L; Szulc, AB; Klajnert, B; Bryszewska, M,期刊：Drug Development Research, 页码：383-394 , 文章类型： Article，,卷期：2010年71-7] Purine and pyrimidine nucleoside analogs (NAs) are antimetabolites commonly used in cancer therapy. Administered as prodrugs, NAs permeate the mambrane using specialized transporters. Following phosphorylation, they inte... A Study Design With Conditional, Serially Assessed Co-primary Endpoints: An Application to a Single-Arm, Pilot Non-Hodgkin's Lymphoma Trial [作者：Mahnken, JD; Wick, JA; Gajewski, BJ; Mayo, MS,期刊：Drug Development Research, 页码：395-403 , 文章类型： Article，,卷期：2010年71-7] Optimizing study designs is an important responsibility for applied statisticians supporting clinical trials. We describe the study design for an early-phase non-Hodgkin's lymphoma trial with two co-primary endpoints; ho... Ligand Binding Sensitivity of the Extracellular Loop Two of the Cannabinoid Receptor 1 [作者：Bertalovitz, AC; Ahn, KH; Kendall, DA,期刊：Drug Development Research, 页码：404-411 , 文章类型： Article，,卷期：2010年71-7] The cannabinoid receptor one (CB1) is a class A G-protein-coupled receptor thought to bind ligands primarily within its helical bundle. Evidence suggests, however, that the extracellular domain may also play a role. We h... Anti-inflammatory and Antiproliferative Activities of Crude Extract and Its Fractions of the Defensive Secretion From the Mediterranean Sponge, Spongia officinalis [作者：Dellai, A; Laroche-Clary, A; Mhadhebi, L; Robert, J; Bouraoui, A,期刊：Drug Development Research, 页码：412-418 , 文章类型： Article，,卷期：2010年71-7] The fact that conventional and newly emerging treatment procedures like chemotherapy, catalytic therapy, photodynamic therapy, and radiotherapy have not succeeded in reversing the outcome of many cancers alternative trea...